Progyny (NASDAQ:PGNY) Reaches New 12-Month Low – Here’s Why

Progyny, Inc. (NASDAQ:PGNY) shares hit a new 52-week low on Friday . The stock traded as low as $16.75 and last traded at $17.6240, with a volume of 2169972 shares. The stock had previously closed at $22.25.

Key Headlines Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Q4 results beat expectations — Progyny reported $0.48 GAAP EPS versus ~$0.38 consensus and revenue of $318.4M (above estimates), showing year-over-year revenue growth. Zacks: Q4 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management raised EPS guidance — Q1 EPS guide of $0.420–$0.450 and FY26 EPS guide of $1.830–$1.950 both exceed prior consensus, signaling improved profitability expectations. Press Release: Q4 Results & Guidance
• Positive Sentiment: Cash generation and buybacks — the company generated record operating cash flow for the full year and has repurchased roughly 6.5M shares under its authorization, which supports shareholder returns. Press Release: Cash Flow & Buybacks
• Neutral Sentiment: Full-year revenue guide is roughly in line with expectations (~$1.4B), so long-term top-line growth projection was not meaningfully changed. Press Release: FY Guidance
• Negative Sentiment: Q1 revenue guide materially below Street — management set Q1 revenue at $319M–$332M versus consensus near ~$345M, creating the main catalyst for the sell-off as investors expect a near-term top-line slowdown. Press Release: Q1 Revenue Guidance
• Negative Sentiment: Rising short interest and sentiment pressure — short interest jumped ~41% in February (to ~5.1% of float), increasing selling pressure and the potential for amplified downside on disappointing near-term metrics. Yahoo: Assessing Valuation After Share Weakness
• Negative Sentiment: Technical/valuation context — shares were already under pressure relative to recent moving averages and the stock’s recovery may be constrained until near-term revenue visibility improves. Yahoo: Earnings Call Highlights

Analyst Upgrades and Downgrades

PGNY has been the subject of several recent research reports. Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Canaccord Genuity Group increased their price objective on shares of Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a research note on Monday, November 17th. Truist Financial upgraded Progyny from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a report on Thursday, January 8th. BTIG Research reiterated a “buy” rating on shares of Progyny in a report on Wednesday, January 21st. Finally, Zacks Research cut Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.80.

Progyny Stock Performance

The company has a market cap of $1.49 billion, a P/E ratio of 27.79, a P/E/G ratio of 1.35 and a beta of 0.96. The business’s 50-day moving average price is $24.08 and its 200 day moving average price is $23.13.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.10. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The business had revenue of $318.40 million during the quarter, compared to the consensus estimate of $314.26 million. During the same period last year, the business posted $0.42 EPS. Progyny’s revenue was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Equities research analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PGNY. Wellington Management Group LLP boosted its position in Progyny by 260.9% during the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after purchasing an additional 1,621,688 shares during the period. Loomis Sayles & Co. L P acquired a new stake in shares of Progyny during the 4th quarter worth about $19,917,000. Barclays PLC boosted its holdings in shares of Progyny by 79.2% during the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock worth $33,904,000 after buying an additional 696,447 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Progyny by 37.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after buying an additional 545,431 shares during the period. Finally, Jupiter Asset Management Ltd. acquired a new position in Progyny in the 2nd quarter valued at about $10,525,000. 94.93% of the stock is owned by institutional investors and hedge funds.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.